Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed. In this international, multicenter trial, we randomly assigned 400 patients with severe symptomatic ...

"US transcatheter tricuspid valve repair market grows by over 50% since launch in Q2 2024" was originally created and ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...

Safe, effective one-year outcomes in severe tricuspid regurgitation, enhancing symptoms and reducing admissions.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after ...

The Evoque transcatheter tricuspid valve replacement (TTVR) system continued to show significant benefits 1 year after implant, according to an update from the TRISCEND II trial. Among study ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England ...

MONDAY, Nov. 4, 2024 (HealthDay News) -- Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study ...

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement (TTVR) plus optimal medical therapy (OMT) yields substantial improvement ...

Join us for a discussion on the new data from TCT 2023 on transcatheter tricuspid valve replacement with the Columbia Structural Heart and Valve team. In this episode, delve into not only the latest ...

Recently, the FDA approved the first ever Transcatheter Tricuspid Valve Replacement (TTVR) device, Evoque. UCLA hopes to offer the Evoque system in the near future. To learn more about UCLA Health ...